Amgen reports Phase 3 results and Amgen stock sits at EUR 358.63 versus EUR 358.50
Published on 10/03/2026 at 11:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen reported positive topline results from the Phase 3 OASIZ 301 study for dazodalibep on September 22, 2026, according to an Amgen release. Separately, Amgen's shares were EUR 358.63 in weekend trading at Lang & Schwarz at 11:21 a.m. CEST on October 3, 2026, up plus 0.04 percent versus the EUR 358.50 close at Lang & Schwarz on October 2, 2026.
Weekend trading
The Lang & Schwarz bid was EUR 358.25 and the ask was EUR 359.00 at 11:21 a.m. CEST on October 3, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Amgen stock.
Latest clinical development
Amgen said the OASIZ 301 study met its primary endpoint at Week 48, showing statistically significant and clinically meaningful improvement in systemic disease activity measured by the EULAR Sjögren's Syndrome Disease Activity Index. The company said improvements were observed as early as Week 4 and were sustained through Week 48. The study evaluated adults with Sjögren's disease and moderate-to-severe systemic disease activity. These details were reported in the company's release.
Development timeline
Amgen said detailed OASIZ 301 data will be presented at an upcoming medical meeting. The company also said its Phase 3 OASIZ 303 study in moderate-to-severe symptomatic Sjögren's disease is expected to complete in the fourth quarter of 2026, according to the release.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
